I kēia mau lā koke nei, ua loaʻa i kahi mea maʻi me ke kanesa pancreatic holomua i hāʻule i nā laina lapaʻau he nui ma mua ka emi mau ʻana o ka puʻupuʻu ma hope o ka loaʻa ʻana o ka lāʻau lapaʻau KD-496 CAR-T cell, me ke kala ʻana i hōʻoia ʻia i mālama ʻia ma 180 mau lā ma hope o ka mālama ʻana.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Leka uila:myimmnet@163.com
Ua ʻike ʻia ka maʻi, he wahine 73 makahiki, i Iulai 2021 me kahi puʻupuʻu poʻo pancreatic i hele pū ʻia me ka pale ʻana o ka ʻauwai bile haʻahaʻa. Ua hana ʻia ʻo ia i kahi duodenectomy, kahi i loaʻa ai kahi puʻupuʻu paʻa ma kahi o 3 cm ka nui ma ke kaʻina hana uncinate poʻo pancreatic. Ua hōʻoia ka hoʻokolokolo pathological i ka adenocarcinoma differentiated moderately. Ma hope o ke ʻoki ʻana, ua loaʻa iā ia ka paclitaxel albumin-bound (nab-paclitaxel) i hui pū ʻia me ka chemotherapy S-1, a ukali ʻia e M108 + nab-paclitaxel + gemcitabine a me LM108 i hui pū ʻia me toripalimab. He mōʻaukala kona o ka schizophrenia a me ka maʻi diabetes, ʻelua i kāohi maikaʻi ʻia me ka lāʻau lapaʻau.
I Pepeluali 2025, ua loaʻa i ka mea maʻi kahi hoʻokomo ʻana o nā pūnaewele KD-496 CAR-T. I ka loiloi mua ʻana o ka puʻupuʻu i ʻehā pule ma hope mai, ʻoiai kona mau makahiki kiʻekiʻe a me ke kaumaha o ka puʻupuʻu (ka lesion pahuhopu kumu o 58 mm), ua emi ka lesion pahuhopu ma 34.5% mai ka baseline. I ka lā 60, ua emi hou ka lesion pahuhopu ma 37.9%, a i nā lā 90 a me 180, ua hoʻomau ka emi ʻana o ka puʻupuʻu ma 44.8%, e mālama ana i kahi pane hapa (PR) me ka ʻole o ka ʻona gastrointestinal a i ʻole neurological.
Ua hana ʻia kekahi maʻi ʻaʻai ʻōpū he 70 ona makahiki i ke ʻoki kino i Pepeluali 2023, me ka pathology postoperative e hōʻike ana i kahi adenocarcinoma ulcerative maʻalahi a maikaʻi ʻole i hoʻokaʻawale ʻia i hoʻopili mua ʻia i nā lymph nodes, ka peritoneum, a me nā māmā ʻelua, me ka ascites a me ka pleural effusion (maʻi holomua, metastatic ākea). ʻEwalu pule ma hope o ke ʻoki kino, ua loaʻa iā ia ka chemotherapy SOX (oxaliplatin + S-1), akā ua holomua kona kūlana. ʻO nā hoʻāʻo ma hope me PX (paclitaxel) + PD-1 (immunotherapy) no ʻehā mau pōʻaiapuni, a ukali ʻia e capecitabine + nivolumab, ʻaʻole i hiki ke hoʻōki i ka holomua. ʻO ka hope loa, ua lawelawe ʻia ʻo nivolumab + fruquintinib (kahi lāʻau anti-angiogenic), akā me ka palena o ka hopena.
I ka lā 28 o ka lāʻau lapaʻau CAR-T, ua emi ka puʻupuʻu ma 47.3% i hoʻohālikelike ʻia me ka mālama mua ʻana, e hoʻokō ana i kahi pane hapa hohonu (PR). I ka lā 60, ua hoʻomau ka emi ʻana o ka puʻupuʻu ma 41.9%, e mālama ana i kahi PR i hōʻoia ʻia, e hōʻike ana i ka mālama mau a me ka maikaʻi.
Ua hana ʻia kekahi maʻi kanesa ʻōpū he 55 makahiki i ka laparoscopic radical gastrectomy i Nowemapa 2023, me ka pathology postoperative e hōʻike ana i ka adenocarcinoma i hoʻokaʻawale maikaʻi ʻole ʻia me ka hapa signet-ring cell carcinoma (malignant nui). Ua hoʻāʻo ʻo ia i nā regimen chemotherapy + immunotherapy he nui, me ka oxaliplatin + capecitabine + sintilimab, oxaliplatin + leucovorin + sintilimab, nab-paclitaxel + sintilimab + fruquintinib, a me ka irinotecan monotherapy. Eia naʻe, i Pepeluali 2025, ua holomua koke kona kūlana, e hoʻolilo ana i nā lāʻau lapaʻau maʻamau i mea ʻole.
A laila ua loaʻa iā ia ka lāʻau lapaʻau CAR-T cell, a ma ka lā 28, ua emi ka puʻupuʻu ma 31.8% i hoʻohālikelike ʻia me ka mālama mua ʻana, e hoʻokō ana i kahi pane hapa (PR), me ka hoʻokō pono ʻana i ka kaohi maʻi.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Leka uila:myimmnet@163.com
Ka manawa hoʻouna: Iulai-31-2025